Skip to main navigation Skip to search Skip to main content

Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma

  • S Guan
  • , B Liu
  • , C Zhang
  • , K-H Lee
  • , S Sun
  • , J Wei

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

The present study was undertaken to develop an in-house enzyme-linked immunosorbent assay (ELISA) using human leukocyte antigen class II restricted epitopes to test circulating autoantibodies to CD25 as a biomarker for esophageal cancer.
Original languageEnglish
Pages (from-to)825-9
Number of pages5
JournalClinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Volume15
Issue number10
DOIs
Publication statusPublished - Oct 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this